newsfilter
← Latest News
Business Wire·

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies Enhanced clinical leadership team with